PMID- 20653404
OWN - NLM
STAT- MEDLINE
DCOM- 20100818
LR  - 20181201
IS  - 1532-4192 (Electronic)
IS  - 0735-7907 (Linking)
VI  - 28 Suppl 1
DP  - 2010
TI  - Challenges in clinical patient management.
PG  - 14-27
LID - 10.3109/07357907.2010.501648 [doi]
AB  - The use of endocrine therapy in breast cancer represents one of the earliest 
      molecular targeting strategies used in cancer treatment. Tamoxifen, a selective 
      estrogen-receptor (ER) modulator, has been the standard of care for women with 
      receptor-positive breast cancer for the last 30 years. Tamoxifen suppresses the 
      estrogen-dependent growth of breast cancer cells by specifically targeting the 
      ER. Because of estrogenic effects, tamoxifen does not increase the risk of 
      osteoporosis, but it can lead to endometrial cancer and thromboembolism. The 
      third-generation aromatase inhibitors (AIs) exert their tumor antiproliferative 
      action by targeting an enzyme critical for estrogen biosynthesis. The AIs thus 
      have a different mechanism of action than tamoxifen, and a different safety 
      profile. The majority of adverse events (AEs) related to the AIs are mild to 
      moderate. Most of these AEs are common to menopause and are predictable and 
      manageable. This review looks at AI-associated side effects and current clinical 
      management strategies, with a particular emphasis on managing bone health. 
      Compliance with long-term therapy, strategies to improve adherence, and 
      considerations in elderly patients with hormone-responsive breast cancer are also 
      discussed.
FAU - Aapro, Matti S
AU  - Aapro MS
AD  - IMO Clinique De Genolier, Institut Multidisciplinaire d'Oncologie, Genolier, 
      Switzerland. maapro@genolier.net
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Cancer Invest
JT  - Cancer investigation
JID - 8307154
RN  - 0 (Aromatase Inhibitors)
RN  - 0 (Diphosphonates)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - KM2Z91756Z (Risedronic Acid)
RN  - M2F465ROXU (Etidronic Acid)
RN  - UMD7G2653W (Ibandronic Acid)
SB  - IM
MH  - Aromatase Inhibitors/adverse effects/therapeutic use
MH  - Bone Density
MH  - Breast Neoplasms/*drug therapy/mortality
MH  - Clinical Trials as Topic
MH  - Diphosphonates/therapeutic use
MH  - Etidronic Acid/analogs & derivatives/therapeutic use
MH  - Female
MH  - Humans
MH  - Ibandronic Acid
MH  - Medication Adherence
MH  - Osteoporosis/prevention & control
MH  - Risedronic Acid
MH  - Tamoxifen/therapeutic use
RF  - 137
EDAT- 2010/08/07 06:00
MHDA- 2010/08/19 06:00
CRDT- 2010/07/27 06:00
PHST- 2010/07/27 06:00 [entrez]
PHST- 2010/08/07 06:00 [pubmed]
PHST- 2010/08/19 06:00 [medline]
AID - 10.3109/07357907.2010.501648 [doi]
PST - ppublish
SO  - Cancer Invest. 2010;28 Suppl 1:14-27. doi: 10.3109/07357907.2010.501648.